person · Reporting owner
Fairmount Healthcare Fund GP LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director | March 28, 2024 | April 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viridian Therapeutics, Inc.\DE
Report date March 28, 2024 · Filed April 01, 2024
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFairmount Healthcare Fund LP | 0 |
Reported balance
After 2024-03-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-03-28 · Other · Disposed 5,859 · Balance 0 F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectFairmount Healthcare Fund II LP | 1,845,813 |
Reported balance
After 2024-03-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-03-28 · Other · Acquired 5,859 · Balance 1,845,813 F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Series A Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund LP | 0 |
Reported balance
After 2024-03-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-28 · Other · Disposed 21,999 · Balance 0 F4: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
| Series A Non-Voting Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II LP | 133,191 |
Reported balance
After 2024-03-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-28 · Other · Acquired 21,999 · Balance 133,191 F4: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II").
F2: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F3: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F4: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 21,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II LP Disclosed balance after: 133,191 Underlying: Common Stock · 1,466,673 shares Expires not disclosed F4 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F4 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F4 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 21,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund LP Disclosed balance after: 0 Underlying: Common Stock · 1,466,673 shares Expires not disclosed F4 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F4 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F4 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherCommon Stock | 5,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,845,813 F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 18:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | OtherCommon Stock | 5,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-039599 · ownership.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 0 F1 · kind: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F1 · price: On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP ("Fund I"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP ("Fund II"). F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 18:44 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 476,190 | $21.00 | $9,999,990.00 |
DisclosureSEC source: 0000950170-24-007123 · ownership.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,839,954 F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 21:05 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantSeries B Non-Voting Convertible Preferred Stock · Derivative | 48,463 | $825.37 | $40,000,129.24 |
DisclosureSEC source: 0000950170-23-057692 · ownership.xml · derivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II LP Disclosed balance after: 48,463 Underlying: Common Stock · 3,231,028.21 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F2 · shares: The shares of Series B non-voting convertible preferred stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended. F1 · derivative.exercise_date: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F1 · derivative.expiration_date: Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and Series B non-voting convertible preferred stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 16:32 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 425,531 | $23.50 | $9,999,978.50 |
DisclosureSEC source: 0001104659-22-092992 · tm2224209-1_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · 10% owner Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 1,363,764 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 09:30 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | PurchaseCommon Stock | 909,000 | $11.00 | $9,999,000.00 |
DisclosureSEC source: 0000899243-21-037255 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 938,233 F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 28,843 | $465.96 | $13,439,684.28 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 111,192 Underlying: Common Stock · 28,483,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 11:53 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | PurchaseSeries A Non-Voting Convertible Preferred Stock · Derivative | 5,494 | $465.96 | $2,559,984.24 |
DisclosureSEC source: 0000899243-20-029904 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 21,999 Underlying: Common Stock · 5,494,000 shares Expires not disclosed F3 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. F1 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 82,349 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 82,349 Underlying: Common Stock · 82,349,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 16,505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · derivative · entry 3 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 16,505 Underlying: Common Stock · 16,505,000 shares Expires not disclosed F5 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F5 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F5 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherCommon Stock | 438,502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund II LP Disclosed balance after: 438,502 F2 · kind: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F2 · price: On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund II LP ("Fund II") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock. F4 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 11:30 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherCommon Stock | 87,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029660 · doc4.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · See Remarks Fairmount Healthcare Fund GP LLC · CIK 0001830383 · Director · See Remarks Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · See Remarks Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · See Remarks Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Fairmount Healthcare Fund LP Disclosed balance after: 87,891 F1 · kind: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F1 · price: On October 27, 2020, Issuer completed its merger ("Merger") with Viridian Therapeutics, Inc. ("Veridian"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, Fairmount Healthcare Fund LP ("Fund I") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock. F3 · ownership.nature: Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.